Detalhe da pesquisa
1.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 678-689, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848462
2.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Am J Hematol
; 95(4): 362-371, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868245
3.
PI3K inhibitors in haematological malignancies.
Lancet Oncol
; 23(8): e365, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901826
4.
Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Ophthalmology
; 121(1): 202-208, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24084497
5.
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Clin Pharmacol Ther
; 115(5): 1092-1104, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226495
6.
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
CPT Pharmacometrics Syst Pharmacol
; 12(11): 1666-1686, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37389853
7.
A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up.
Aging Male
; 15(4): 198-207, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22834649
8.
Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34568715
9.
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Blood Adv
; 5(3): 823-828, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33560394
10.
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Leukemia
; 34(8): 2184-2197, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32060403
11.
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Leukemia
; 38(2): 469-472, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38200221
12.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
J Clin Oncol
; 35(35): 3898-3905, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28976790
13.
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Am J Ophthalmol
; 158(5): 1032-8, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25068637
14.
VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.
Br J Ophthalmol
; 97(3): 278-84, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23298885
15.
An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women.
Menopause
; 19(7): 799-803, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22228322
16.
Cerebral amyloid-ß PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Lancet Neurol
; 10(5): 424-35, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21481640
17.
Reply: To PMID 25068637.
Am J Ophthalmol
; 159(3): 608, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25681024